anti-IL-13Ralpha2 mAbs (ProAlt)

N/A

Report date: 2025/06/11 10:57:09

Base Information

Drug Nameanti-IL-13Ralpha2 mAbs (ProAlt)
Drug Alias NamePA-413APA-413B
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulators
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsColorectal NeoplasmsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProtein Alternatives Sl
China Registration ClassN/A

Develop Information

Active CompaniesProtein Alternatives Sl
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A